Stryker Co. (NYSE:SYK) Shares Sold by Sigma Investment Counselors Inc.

Sigma Investment Counselors Inc. trimmed its position in Stryker Co. (NYSE:SYK) by 0.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 41,631 shares of the medical technology company’s stock after selling 297 shares during the quarter. Stryker makes up approximately 0.9% of Sigma Investment Counselors Inc.’s portfolio, making the stock its 26th biggest position. Sigma Investment Counselors Inc.’s holdings in Stryker were worth $14,989,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Private Advisor Group LLC raised its holdings in shares of Stryker by 3.4% in the third quarter. Private Advisor Group LLC now owns 15,967 shares of the medical technology company’s stock worth $5,768,000 after buying an additional 526 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Stryker by 15.6% in the third quarter. Assenagon Asset Management S.A. now owns 10,304 shares of the medical technology company’s stock worth $3,722,000 after buying an additional 1,392 shares during the last quarter. Global Trust Asset Management LLC purchased a new position in shares of Stryker during the third quarter worth $69,000. DT Investment Partners LLC raised its holdings in shares of Stryker by 114.3% during the third quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock worth $49,000 after purchasing an additional 72 shares during the last quarter. Finally, Trueblood Wealth Management LLC raised its holdings in shares of Stryker by 7.6% during the third quarter. Trueblood Wealth Management LLC now owns 2,841 shares of the medical technology company’s stock worth $1,026,000 after purchasing an additional 200 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Down 1.0 %

Shares of NYSE SYK opened at $382.59 on Friday. The firm has a market cap of $145.99 billion, a price-to-earnings ratio of 49.30, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company’s 50-day simple moving average is $378.07 and its 200-day simple moving average is $368.99. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the firm earned $3.46 EPS. Equities analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker’s payout ratio is presently 43.30%.

Wall Street Analyst Weigh In

SYK has been the subject of several recent research reports. JPMorgan Chase & Co. raised their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Citigroup lifted their price objective on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Truist Financial lifted their price objective on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Stifel Nicolaus lifted their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Finally, Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $422.15.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.